share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募资说明书
美股SEC公告 ·  04/12 13:13

Moomoo AI 已提取核心信息

Allarity Therapeutics Inc. has filed a new prospectus supplement on April 12, 2024, to increase the maximum aggregate offering price of its common stock from $2,350,000 to $3,200,000. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company is offering the common stock through Ascendiant Capital Markets, LLC, as per the At-The-Market Issuance Sales Agreement. As of February 28, 2024, the market value of Allarity's common stock held by non-affiliates was approximately $9.64 million, with a public float of 1,126,573 shares. The company has already sold $2,167,957 worth of common stock in the past 12 months and can sell up to an additional $1,046,514 under the current SEC guidelines. The sale of shares is capped at one-third of the aggregate market value of the common stock held by non-affiliates within any 12-month period, provided the public float remains below $75 million.
Allarity Therapeutics Inc. has filed a new prospectus supplement on April 12, 2024, to increase the maximum aggregate offering price of its common stock from $2,350,000 to $3,200,000. This filing amends the prior prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The company is offering the common stock through Ascendiant Capital Markets, LLC, as per the At-The-Market Issuance Sales Agreement. As of February 28, 2024, the market value of Allarity's common stock held by non-affiliates was approximately $9.64 million, with a public float of 1,126,573 shares. The company has already sold $2,167,957 worth of common stock in the past 12 months and can sell up to an additional $1,046,514 under the current SEC guidelines. The sale of shares is capped at one-third of the aggregate market value of the common stock held by non-affiliates within any 12-month period, provided the public float remains below $75 million.
Allarity Therapeutics Inc.已于2024年4月12日提交了新的招股说明书补充文件，将其普通股的最高总发行价从235万美元提高到320万美元。本文件修订了先前于2023年11月29日发布的招股说明书和2024年3月19日的招股说明书补充文件。根据市场发行销售协议，该公司通过Ascendiant Capital Markets, LLC发行普通股。截至2024年2月28日，非关联公司持有的Allarity普通股的市值约为964万美元，公开流通量为1,126,573股。在过去的12个月中，该公司已经出售了价值2,167,957美元的普通股，根据美国证券交易委员会目前的指导方针，该公司最多可以再出售1,046,514美元的普通股。只要公众持股量保持在7,500万美元以下，出售股票的上限为非关联公司在任何12个月内持有的普通股总市值的三分之一。
Allarity Therapeutics Inc.已于2024年4月12日提交了新的招股说明书补充文件，将其普通股的最高总发行价从235万美元提高到320万美元。本文件修订了先前于2023年11月29日发布的招股说明书和2024年3月19日的招股说明书补充文件。根据市场发行销售协议，该公司通过Ascendiant Capital Markets, LLC发行普通股。截至2024年2月28日，非关联公司持有的Allarity普通股的市值约为964万美元，公开流通量为1,126,573股。在过去的12个月中，该公司已经出售了价值2,167,957美元的普通股，根据美国证券交易委员会目前的指导方针，该公司最多可以再出售1,046,514美元的普通股。只要公众持股量保持在7,500万美元以下，出售股票的上限为非关联公司在任何12个月内持有的普通股总市值的三分之一。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间